Intron Biotechnology signs material transfer agreement in Europe for next-generation SC platform 'pHyal20'
Predicted impact: Low
Material transfer agreement for a platform technology; small and vague commercially.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.